Literature DB >> 16952434

Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB-IIA cervical cancer.

N Behtash1, Z Nazari, H Ayatollahi, M Modarres, F Ghaemmaghami, A Mousavi.   

Abstract

AIM: The aim of this study was evaluation of the efficacy of neoadjuvant chemotherapy (NACT) and radical hysterectomy on long-term survival in stage IB-IIA locally advanced cervical cancer as compared with radical surgery alone.
METHODS: We reviewed all patients with cervical cancer stage IB-IIA who were treated with two treatment modalities, i.e. NACT followed by radical hysterectomy and lymphadenectomy, and radical hysterectomy alone between March 1996 and March 2004. There were 22 patients in the NACT group (group 1) and 160 patients in the immediate radical surgery group (group 2). All patients in group 1 were followed for more than 108months, and long-term survival and factors affecting recurrence were evaluated.
RESULTS: Nineteen patients in the NACT arm underwent radical surgery. Pelvic lymph node metastasis was found in 8 patients in this group and in 36 in the radical surgery group. Eighteen patients in the NACT group and 96 patients in the radical surgery group were scheduled for adjuvant postoperative chemoradiation. During the 9-year follow-up, recurrence rate was 47.1% and 30.2% in NACT and control groups, respectively. In the NACT group lymph node metastasis was a significant independent risk factor for recurrence. Overall survival in the NACT arm was not statistically significantly lower than the control arm (p=0.06).
CONCLUSION: NACT did not improve long-term overall survival of bulky early-stage cervical cancer patients compared to primary radical surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952434     DOI: 10.1016/j.ejso.2006.07.012

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

1.  The safety and efficacy of the preoperative neoadjuvant chemotherapy for patients with cervical cancer: a systematic review and meta analysis.

Authors:  Du He; Chunyan Duan; Jun Chen; Lin Lai; Jiaquan Chen; Dian Chen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Proteomic identification of neoadjuvant chemotherapy-related proteins in bulky stage IB-IIA squamous cervical cancer.

Authors:  Shuangwei Zou; Qi Shen; Ying Hua; Wenxiao Jiang; Wenwen Zhang; Xueqiong Zhu
Journal:  Reprod Sci       Date:  2013-04-18       Impact factor: 3.060

3.  Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

4.  Experience in stage IB2 cervical cancer and review of treatment.

Authors:  Taner Turan; Burcu Aykan Yıldırım; Gökhan Tulunay; Nurettin Boran; Ferah Yıldız; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

5.  Could the extent of lymphadenectomy be modified by neoadjuvant chemotherapy in cervical cancer? A large-scale retrospective study.

Authors:  Ting Hu; Xiong Li; Qinghua Zhang; Kecheng Huang; Yao Jia; Ru Yang; Fangxu Tang; Qiang Tian; Ding Ma; Shuang Li
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: a systematic review and meta-analysis.

Authors:  Hui Zhao; Yue He; Shu-Li Yang; Qun Zhao; Yu-Mei Wu
Journal:  Onco Targets Ther       Date:  2019-03-07       Impact factor: 4.147

7.  Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients.

Authors:  Lucely Cetina; Alicia Garcia-Arias; Myrna Candelaria; David Cantú; Lesbia Rivera; Jaime Coronel; Blanca Bazan-Perkins; Vladimir Flores; Aaron Gonzalez; Alfonso Dueñas-González
Journal:  World J Surg Oncol       Date:  2009-02-16       Impact factor: 2.754

8.  Neoadjuvant chemotherapy for locally advanced cervical cancer.

Authors:  Takashi Iwata; Azumi Miyauchi; Yukako Suga; Hiroshi Nishio; Masaru Nakamura; Akiko Ohno; Nobumaru Hirao; Tohru Morisada; Kyoko Tanaka; Hiroki Ueyama; Hidemichi Watari; Daisuke Aoki
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

9.  Adjuvant chemotherapy for early-stage cervical cancer.

Authors:  Hiroshi Asano; Yukiharu Todo; Hidemichi Watari
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

10.  Effect of neoadjuvant chemotherapy followed by surgery for FIGO stage I-II cervical cancer: a meta-analysis.

Authors:  Shu-Li Yang; Ling Chen; Yue He; Hui Zhao; Yu-Mei Wu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.